A. Alonso and M. Hernán, Temporal trends in the incidence of multiple sclerosis: A systematic review, Neurology, vol.71, issue.2, pp.129-135, 2008.
DOI : 10.1212/01.wnl.0000316802.35974.34

R. Alvarez-lafuente, M. García-montojo, D. Las-heras, V. Domínguez-mozo, M. Bartolome et al., Herpesviruses and human endogenous retroviral sequences in the cerebrospinal fluid of multiple sclerosis patients, Multiple Sclerosis Journal, vol.17, issue.5, pp.595-601, 2008.
DOI : 10.1177/1352458507086425

A. Ascherio and K. Munger, Environmental risk factors for multiple sclerosis. Part I: The role of infection, Annals of Neurology, vol.66, issue.suppl, pp.288-299, 2007.
DOI : 10.1002/ana.21117

B. Audoin and O. Casez, Critères diagnostiques de la sclérose en plaques : l'IRM et la clinique, Neurologies, vol.144, issue.15, pp.18-26, 2012.

F. Barkhof, M. Filippi, D. H. Miller, P. Scheltens, A. Campi et al., Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis, Brain, vol.120, issue.11, pp.2059-2069, 1997.
DOI : 10.1093/brain/120.11.2059

A. Beck, C. Ward, M. Mendelson, J. Mock, and J. Erbaugh, An Inventory for Measuring Depression, Archives of General Psychiatry, vol.4, issue.6, pp.561-571, 1961.
DOI : 10.1001/archpsyc.1961.01710120031004

P. Bourque and D. Beaudette, ??tude psychometrique du questionnaire de d??pression de Beck aupr??s d'un ??chantillon d'??tudiants universitaires francophones., Canadian Journal of Behavioural Science/Revue canadienne des sciences du comportement, vol.14, issue.3, pp.211-218, 1982.
DOI : 10.1037/h0081254

D. Brassat, Physiopathologie de la scl??rose en plaques, La Presse M??dicale, vol.39, issue.3, pp.341-348, 2010.
DOI : 10.1016/j.lpm.2009.12.001

B. Brochet, Place de l???EDSS dans l?????valuation pr??coce du handicap, Revue Neurologique, vol.165, pp.173-179, 2009.
DOI : 10.1016/S0035-3787(09)72131-9

M. Brodsky, S. Nazarian, S. Orengo-nania, G. Hutton, E. Buckley et al., Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up, Arch. Neurol, vol.65, pp.727-732, 2008.

J. Burton, O. Connor, P. Hohol, M. Beyene, and J. , Oral versus intravenous steroids for treatment of relapses in multiple sclerosis, Cochrane Database Syst Rev, p.6921, 2009.

P. Cabre, Environmental changes and epidemiology of multiple sclerosis in the French West Indies, Journal of the Neurological Sciences, vol.286, issue.1-2, pp.58-61, 2009.
DOI : 10.1016/j.jns.2009.04.039

I. Carlyle, Multiple sclerosis: a geographical hypothesis, Medical Hypotheses, vol.49, issue.6, pp.477-486, 1997.
DOI : 10.1016/S0306-9877(97)90065-7

D. Chard, C. M. Dalton, J. Swanton, L. Fisniku, K. A. Miszkiel et al., MRI only conversion to multiple sclerosis following a clinically isolated syndrome, Journal of Neurology, Neurosurgery & Psychiatry, vol.82, issue.2, pp.176-179, 2011.
DOI : 10.1136/jnnp.2010.208660

E. Chiao and K. Meyer, Cost effectiveness and budget impact of natalizumab in patients with relapsing multiple sclerosis, Current Medical Research and Opinion, vol.25, issue.6, pp.1445-1454, 2009.
DOI : 10.1185/03007990902876040

P. Clavelou, C. Auclair, F. Taithe, and L. Gerbaud, La qualit?? de vie des patients souffrant de scl??rose en plaques, Revue Neurologique, vol.165, issue.4, pp.123-128, 2009.
DOI : 10.1016/S0035-3787(09)72123-X

C. Jeffrey, A. , B. Frederik, C. Giancarlo, H. Hartung et al., Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis, N. Engl. J. Med, vol.362, pp.402-415, 2010.

G. Comi, M. Filippi, F. Barkhof, L. Durelli, G. Edan et al., Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study, The Lancet, vol.357, issue.9268, pp.1576-1582, 2001.
DOI : 10.1016/S0140-6736(00)04725-5

G. Comi, V. Martinelli, M. Rodegher, L. Moiola, O. Bajenaru et al., Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial, The Lancet, vol.374, issue.9700, pp.1503-1511, 2009.
DOI : 10.1016/S0140-6736(09)61259-9

C. Giancarlo, D. Stefano, N. , F. Mark, S. et al., Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial, Lancet Neurol, vol.11, pp.33-41, 2012.

C. Alastair and A. Coles, Multiple sclerosis, Lancet, vol.359, pp.1221-1231, 2002.

C. Alastair and A. Coles, Multiple sclerosis, Lancet, vol.372, pp.1502-1517, 2008.

C. Confavreux and S. Vukusic, Natural history of multiple sclerosis: a unifying concept, Brain, vol.129, issue.3, pp.606-616, 2006.
DOI : 10.1093/brain/awl007

A. Créange and P. Labauge, Handicap social des formes pr??coces de scl??rose en plaques, Revue Neurologique, vol.165, pp.167-172, 2009.
DOI : 10.1016/S0035-3787(09)72130-7

U. Dalgas, E. Stenager, and T. Ingemann-hansen, Review: Multiple sclerosis and physical exercise: recommendations for the application of resistance-, endurance- and combined training, Multiple Sclerosis Journal, vol.29, issue.1, pp.35-53, 2008.
DOI : 10.1191/1352458503ms904oa

G. Dean and M. Elian, Age at immigration to England of Asian and Caribbean immigrants and the risk of developing multiple sclerosis, Journal of Neurology, Neurosurgery & Psychiatry, vol.63, issue.5, pp.565-568, 1997.
DOI : 10.1136/jnnp.63.5.565

G. Ebers, Randomised double-blind placebo-controlled study of interferon ??-1a in relapsing/remitting multiple sclerosis, The Lancet, vol.352, issue.9139, pp.1498-1504, 1998.
DOI : 10.1016/S0140-6736(98)03334-0

M. Elian, S. Nightingale, and G. Dean, Multiple sclerosis among United Kingdom-born children of immigrants from the Indian subcontinent, Africa and the West Indies., Journal of Neurology, Neurosurgery & Psychiatry, vol.53, issue.10, pp.906-911, 1990.
DOI : 10.1136/jnnp.53.10.906

S. Elmståhl, B. Malmberg, and L. Annerstedt, Caregiver's burden of patients 3 years after stroke assessed by a novel caregiver burden scale, Archives of Physical Medicine and Rehabilitation, vol.77, issue.2, pp.177-182, 1996.
DOI : 10.1016/S0003-9993(96)90164-1

F. Oscar, K. Baumstarck-barrau, M. Simeoni, and P. Auquier, Patient characteristics and determinants of quality of life in an international population with multiple sclerosis: assessment using the MusiQoL and SF-36 questionnaires, Mult. Scler, vol.17, pp.1238-1249, 2011.

A. Fillet, P. Lozeron, H. Agut, O. Lyon-caen, and R. Liblau, HHV-6 and multiple sclerosis, Nature Medicine, vol.171, issue.5, pp.537-538, 1998.
DOI : 10.1016/0166-0934(95)01983-9

L. Fisniku, P. Brex, D. Altmann, K. A. Miszkiel, C. Benton et al., Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis, Brain, vol.131, issue.3, pp.808-817, 2008.
DOI : 10.1093/brain/awm329

Y. Fragoso, A. Finkelsztejn, M. Giacomo, L. Russo, and W. Cruz, The effect of multiple sclerosis on the professional life of a group of Brazilian patients, Arquivos de Neuro-Psiquiatria, vol.68, issue.6, pp.914-917, 2010.
DOI : 10.1590/S0004-282X2010000600016

A. Fromont, C. Binquet, L. Clerc, and T. Moreau, ??pid??miologie de la scl??rose en plaques??: la particularit?? fran??aise, Revue Neurologique, vol.165, issue.8-9, pp.671-675, 2009.
DOI : 10.1016/j.neurol.2009.04.003

A. Fromont, C. Binquet, E. Sauleau, I. Fournel, R. Despalins et al., National estimate of multiple sclerosis incidence in France (2001???2007), Multiple Sclerosis Journal, vol.1210, issue.8, pp.1108-1115, 2001.
DOI : 10.3917/pope.701.0139

F. Agnes, B. Christine, E. Sauleau, F. Isabelle, A. Bellisario et al., Geographic variations of multiple sclerosis in France, Brain, vol.133, pp.1889-1899, 2010.

R. Gal, S. Vedula, and R. Beck, Corticosteroids for treating optic neuritis, Cochrane Database Syst Rev, vol.4, p.1430, 2012.

P. Gallien, N. B. Robineau, S. Pétrilli, S. Houedakor, J. Durufle et al., Physical training and??multiple sclerosis, Annales de R??adaptation et de M??decine Physique, vol.50, issue.6, pp.373-376, 2007.
DOI : 10.1016/j.annrmp.2007.04.004

R. Gani, G. Giovannoni, D. Bates, B. Kemball, S. Hughes et al., Cost-Effectiveness Analyses of Natalizumab (Tysabri??) Compared with Other Disease-Modifying Therapies for People with Highly Active Relapsing-Remitting Multiple Sclerosis in the UK, PharmacoEconomics, vol.71, issue.4, pp.617-627, 2008.
DOI : 10.2165/00019053-200826070-00008

S. Gheuens, D. Smith, X. Wang, D. Alsop, R. Lenkinski et al., Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS, Neurology, vol.78, issue.18, pp.1390-1393, 2012.
DOI : 10.1212/WNL.0b013e318253d61e

L. Gorelik, M. Lerner, S. Bixler, M. Crossman, B. Schlain et al., Anti-JC virus antibodies: Implications for PML Risk Stratification, Annals of Neurology, vol.361, issue.suppl, pp.295-303, 2010.
DOI : 10.1002/ana.22128

W. Henderson, E. Schlenk, K. Kim, C. Hadigan, A. Martino et al., Validation of the MOS-HIV as a measure of health-related quality of life in persons living with HIV and liver disease, AIDS Care, vol.22, issue.4, pp.483-490, 2010.
DOI : 10.1080/09540120903207292

R. Hohlfeld and H. Wekerle, Drug Insight: using monoclonal antibodies to treat multiple sclerosis, Nature Clinical Practice Neurology, vol.64, issue.1, pp.34-44, 2005.
DOI : 10.1016/S0167-5699(00)01680-7

URL : http://hdl.handle.net/11858/00-001M-0000-0012-2253-1

C. Honan, R. Brown, D. Hine, L. Vowels, J. Wollin et al., The Multiple Sclerosis Work Difficulties Questionnaire, Multiple Sclerosis Journal, vol.12, issue.6, pp.871-880, 2012.
DOI : 10.1016/j.jns.2005.08.019

L. Jacobs, R. Beck, J. Simon, R. Kinkel, C. Brownscheidle et al., Intramuscular Interferon Beta-1A Therapy Initiated during a First Demyelinating Event in Multiple Sclerosis, New England Journal of Medicine, vol.343, issue.13, pp.898-904, 2000.
DOI : 10.1056/NEJM200009283431301

L. Jacobs, D. Cookfair, R. A. Rudick, R. Herndon, J. Richert et al., Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis, Annals of Neurology, vol.43, issue.3, pp.285-294, 1996.
DOI : 10.1002/ana.410390304

K. Johnson, B. Brooks, J. A. Cohen, C. Ford, J. Goldstein et al., Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind, placebo-controlled trial, Neurology, vol.45, issue.7, pp.1268-1276, 1995.
DOI : 10.1212/WNL.45.7.1268

U. Kallweit, I. Jelcic, N. Braun, H. Fischer, B. Zörner et al., Sustained Efficacy of Natalizumab in the Treatment of Relapsing-Remitting Multiple Sclerosis Independent of Disease Activity and Disability at Baseline, Clinical Neuropharmacology, vol.35, issue.2, pp.77-80, 2012.
DOI : 10.1097/WNF.0b013e31824644e6

L. Kappos, C. H. Polman, M. S. Freedman, G. Edan, H. Hartung et al., Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes, Neurology, vol.67, issue.7, pp.1242-1249, 2006.
DOI : 10.1212/01.wnl.0000237641.33768.8d

K. Ludwig, E. Radue, O. Connor, P. , P. Chris et al., A placebocontrolled trial of oral fingolimod in relapsing multiple sclerosis, N. Engl. J. Med, vol.362, pp.387-401, 2010.

S. Katz and C. Akpom, A Measure of Primary Sociobiological Functions, International Journal of Health Services, vol.2, issue.1, pp.493-508, 1976.
DOI : 10.1093/geront/10.1_Part_1.20

B. Kleinschmidt-demasters, A. Miravalle, J. Schowinsky, J. Corboy, and T. Vollmer, Update on PML and PML-IRIS Occurring in Multiple Sclerosis Patients Treated With Natalizumab, Journal of Neuropathology & Experimental Neurology, vol.71, issue.7, pp.604-617, 2012.
DOI : 10.1097/NEN.0b013e31825caf2c

K. Krysko, O. Connor, and P. , Conclusions:, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, vol.17, issue.03, pp.422-428, 2011.
DOI : 10.1002/ana.410390304

J. Kurtzke, Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS), Neurology, vol.33, issue.11, pp.1444-1452, 1983.
DOI : 10.1212/WNL.33.11.1444

A. Kuspinar, A. Rodriguez, and N. Mayo, The effects of clinical interventions on health-related quality of life in multiple sclerosis: a meta-analysis, Multiple Sclerosis Journal, vol.25, issue.12, pp.1-19, 2012.
DOI : 10.1016/j.jclinepi.2009.03.020

A. Kutzelnigg, C. Lucchinetti, C. Stadelmann, W. Brück, H. Rauschka et al., Cortical demyelination and diffuse white matter injury in multiple sclerosis, Brain, vol.128, issue.11, pp.2705-2712, 2005.
DOI : 10.1093/brain/awh641

A. Langer-gould, R. Popat, S. Huang, K. Cobb, P. Fontoura et al., Clinical and Demographic Predictors of Long-term Disability in Patients With Relapsing-Remitting Multiple Sclerosis, Archives of Neurology, vol.63, issue.12, pp.1686-1691, 2006.
DOI : 10.1001/archneur.63.12.1686

M. Lawton and E. Brody, ASSESSMENT OF OLDER PEOPLE, Nursing Research, vol.19, issue.3, pp.179-186, 1969.
DOI : 10.1097/00006199-197005000-00029

U. Leibowitz, E. Kahana, and M. Alter, MULTIPLE SCLEROSIS IN IMMIGRANT AND NATIVE POPULATIONS OF ISRAEL, The Lancet, vol.294, issue.7634, pp.1323-1325, 1969.
DOI : 10.1016/S0140-6736(69)90863-0

L. Leocani and C. Giancarlo, Neurophysiological markers, Neurological Sciences, vol.124, issue.[Suppl1], pp.218-221, 2008.
DOI : 10.1007/s10072-008-0942-1

E. Leray, J. Yaouanq, L. Page, E. Coustans, M. Laplaud et al., Evidence for a two-stage disability progression in multiple sclerosis, Brain, vol.133, issue.7, pp.1900-1913, 2010.
DOI : 10.1093/brain/awq076

F. D. Lublin and S. C. Reingold, Defining the clinical course of multiple sclerosis: Results of an international survey, Neurology, vol.46, issue.4, pp.907-911, 1996.
DOI : 10.1212/WNL.46.4.907

E. Major, Progressive Multifocal Leukoencephalopathy in Patients on Immunomodulatory Therapies, Annual Review of Medicine, vol.61, issue.1, pp.35-47, 2010.
DOI : 10.1146/annurev.med.080708.082655

G. Mameli, V. Astone, G. Arru, S. Marconi, L. Lovato et al., Brains and peripheral blood mononuclear cells of multiple sclerosis (MS) patients hyperexpress MS-associated retrovirus/HERV-W endogenous retrovirus, but not Human herpesvirus 6, Journal of General Virology, vol.88, issue.1, pp.264-274, 2007.
DOI : 10.1099/vir.0.81890-0

R. Marrie, Environmental risk factors in multiple sclerosis aetiology, The Lancet Neurology, vol.3, issue.12, pp.709-718, 2004.
DOI : 10.1016/S1474-4422(04)00933-0

M. Boneschi, F. Rovaris, M. Capra, R. Comi, and G. , Mitoxantrone for multiple sclerosis, Cochrane Database Syst Rev, p.2127, 2005.

W. Mcdonald, A. Compston, G. Edan, D. Goodkin, H. Hartung et al., Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis, Annals of Neurology, vol.70, issue.1, pp.121-127, 2001.
DOI : 10.1002/ana.1032

E. Mcfadden, M. Horton, H. Ford, G. Gilworth, M. Mcfadden et al., Screening for the risk of job loss in multiple sclerosis (MS): development of an MS-specific Work Instability Scale (MS-WIS), Multiple Sclerosis Journal, vol.6, issue.6, pp.862-870, 2012.
DOI : 10.1002/acr.20272

C. Mchorney, J. Ware, . Jr, and A. Raczek, The MOS 36-Item Short-Form Health Survey (SF-36), Medical Care, vol.31, issue.3, pp.247-263, 1993.
DOI : 10.1097/00005650-199303000-00006

I. Van-der-mei, A. Ponsonby, T. Dwyer, L. Blizzard, R. Simmons et al., PAST SUN EXPOSURE, SKIN PHENOTYPE AND RISK OF MULTIPLE SCLEROSIS, Epidemiology, vol.14, issue.Supplement, p.316, 2003.
DOI : 10.1097/00001648-200309001-00275

A. Melin, O. Outteryck, N. Collongues, H. Zéphir, M. Fleury et al., Effect of natalizumab on clinical and radiological disease activity in a French cohort of patients with relapsing-remitting multiple sclerosis, Journal of Neurology, vol.256, issue.Suppl 3, pp.1215-1221, 2012.
DOI : 10.1007/s00415-011-6339-8

M. David, H. Khan, O. Sheremata, W. Blumhardt, L. Rice et al., A controlled trial of natalizumab for relapsing multiple sclerosis, N. Engl. J. Med, vol.348, pp.15-23, 2003.

K. Myhr and S. Mellgren, Corticosteroids in the treatment of multiple sclerosis, Acta Neurologica Scandinavica, vol.16, pp.73-80, 2009.
DOI : 10.1111/j.1600-0404.2009.01213.x

J. Noseworthy, C. Lucchinetti, M. Rodriguez, and B. Weinshenker, Multiple Sclerosis, New England Journal of Medicine, vol.343, issue.13, pp.938-952, 2000.
DOI : 10.1056/NEJM200009283431307

A. Oturai, N. Koch-henriksen, T. Petersen, P. Jensen, F. Sellebjerg et al., Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study, European Journal of Neurology, vol.14, issue.3, pp.420-423, 2009.
DOI : 10.1111/j.1468-1331.2008.02517.x

O. Olivier, J. Ongagna, H. Zéphir, M. Fleury, A. Lacour et al., Demographic and clinic characteristics of French patients treated with natalizumab in clinical practice, J. Neurol, vol.257, pp.207-211, 2010.

C. Papeix, L. Catherine, and L. Olivier, Traitements actuels de la scl??rose en plaques, La Presse M??dicale, vol.39, issue.3, pp.381-388, 2010.
DOI : 10.1016/j.lpm.2009.05.021

N. Patsopoulos, F. Esposito, J. Reischl, S. Lehr, D. Bauer et al., Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci, Annals of Neurology, vol.10, issue.6, pp.897-912, 2011.
DOI : 10.1002/ana.22609

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3247076

D. Paty and D. Li, Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial, Neurology, vol.43, issue.4, pp.662-667, 1993.
DOI : 10.1212/WNL.43.4.662

T. Perneger, A. Leplège, J. Etter, and A. Rougemont, Validation of a French-language version of the MOS 36-Item Short Form Health Survey (SF-36) in young healthy adults, Journal of Clinical Epidemiology, vol.48, issue.8, pp.1051-1060, 1995.
DOI : 10.1016/0895-4356(94)00227-H

C. Pfleger, E. M. Flachs, . Koch-henriksen, and . Nils, Social consequences of multiple sclerosis. Part 2. Divorce and separation: a historical prospective cohort study, Multiple Sclerosis Journal, vol.24, issue.7, pp.878-882, 2010.
DOI : 10.1093/brain/awh714

P. Claudia, C. Hilt, . Flachs-esben-meulengracht, . Koch-henriksen, and . Nils, Social consequences of multiple sclerosis (1): early pension and temporary unemployment--a historical prospective cohort study, Mult. Scler, vol.16, pp.121-126, 2010.

P. Chris, H. , O. Connor, P. Havrdova, E. Hutchinson et al., A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis, N. Engl. J. Med, vol.354, pp.899-910, 2006.

P. Chris, H. , R. Stephen, C. Banwell, B. Clanet et al., Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria, Ann. Neurol, vol.69, pp.292-302, 2011.

P. Chris, H. , R. Stephen, C. , E. Gilles et al., Diagnostic criteria for multiple sclerosis: 2005 revisions to the 'McDonald Criteria, Ann. Neurol, vol.58, pp.840-846, 2005.

C. Poser, D. Paty, L. Scheinberg, W. Mcdonald, F. Davis et al., New diagnostic criteria for multiple sclerosis: Guidelines for research protocols, Annals of Neurology, vol.122, issue.3, pp.227-231, 1983.
DOI : 10.1002/ana.410130302

N. Putzki, O. Yaldizli, M. Mäurer, S. Cursiefen, S. Kuckert et al., FP33-WE-02 Efficacy of natalizumab in second-line therapy of relapsing remitting multiple sclerosis: results from a multi-center study in German speaking countries, Journal of the Neurological Sciences, vol.285, pp.31-37, 2010.
DOI : 10.1016/S0022-510X(09)70440-X

R. Richard, A. Miller, D. Hass, S. Hutchinson, M. Calabresi et al., Health-related quality of life in multiple sclerosis: effects of natalizumab, Ann. Neurol, vol.62, pp.335-346, 2007.

R. Richard, A. Stuart, W. Calabresi, P. Confavreux, C. Galetta et al., Natalizumab plus interferon beta-1a for relapsing multiple sclerosis, N. Engl. J. Med, vol.354, pp.911-923, 2006.

. Sørensen-per-soelberg, A. Bertolotto, E. Gilles, G. Giovannoni, R. Gold et al., Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab, Multiple Sclerosis Journal, vol.18, issue.2, pp.143-152, 2012.
DOI : 10.1177/1352458511435105

R. Srivastava, M. Aslam, S. Kalluri, L. Schirmer, D. Buck et al., Potassium Channel KIR4.1 as an Immune Target in Multiple Sclerosis, New England Journal of Medicine, vol.367, issue.2, pp.115-123, 2012.
DOI : 10.1056/NEJMoa1110740

S. Sunyaev, A. Lugovskoy, K. Simon, and L. Gorelik, Adaptive Mutations in the JC Virus Protein Capsid Are Associated with Progressive Multifocal Leukoencephalopathy (PML), PLoS Genetics, vol.4, issue.10, p.1000368, 2009.
DOI : 10.1371/journal.pgen.1000368.s004

M. Tintoré, A. Rovira, M. Martínez, J. Rio, P. Díaz-villoslada et al., Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis, AJNR Am J Neuroradiol, vol.21, pp.702-706, 2000.

T. Tourdias, B. Brochet, K. Petry, and V. Dousset, Imagerie par r??sonance magn??tique de l???inflammation du syst??me nerveux central, Revue Neurologique, vol.165, pp.77-87, 2009.
DOI : 10.1016/S0035-3787(09)73952-9

B. Trapp, J. Peterson, R. Ransohoff, R. Rudick, S. Mörk et al., Axonal Transection in the Lesions of Multiple Sclerosis, New England Journal of Medicine, vol.338, issue.5, pp.278-285, 1998.
DOI : 10.1056/NEJM199801293380502

P. Vermersch, The immunology of multiple sclerosis: changing concepts], Rev. Neurol. (Paris), vol.164, issue.2, pp.138-146, 2008.

D. Vernay, L. Gerbaud, S. Biolay, J. Coste, J. Debourse et al., Quality of life and multiple sclerosis: validation of the french version of the self-questionnaire (SEP-59)], Rev. Neurol. (Paris), vol.156, pp.247-263, 2000.

B. Vickrey, R. Hays, R. Harooni, L. Myers, and G. Ellison, A health-related quality of life measure for multiple sclerosis, Quality of Life Research, vol.30, issue.Suppl 1, pp.187-206, 1995.
DOI : 10.1007/BF02260859

S. Vukusic and C. Confavreux, Natural history of multiple sclerosis: risk factors and prognostic indicators, Current Opinion in Neurology, vol.20, issue.3, pp.269-274, 2007.
DOI : 10.1097/WCO.0b013e32812583ad

S. Vukusic and C. Confavreux, The Natural History of Multiple Sclerosis, Presse Med, vol.39, pp.359-362, 2010.
DOI : 10.1201/9780824741846.ch17

C. Willer, D. Dyment, N. Risch, A. Sadovnick, and G. Ebers, Twin concordance and sibling recurrence rates in multiple sclerosis, Proceedings of the National Academy of Sciences, vol.100, issue.22, pp.12877-12882, 2003.
DOI : 10.1073/pnas.1932604100

B. Wood, I. Van-der-mei, A. Ponsonby, F. Pittas, S. Quinn et al., Prevalence and concurrence of anxiety, depression and fatigue over time in multiple sclerosis [Internet] Multiple sclerosis (Houndmills, p.2012, 2012.

P. Young, C. Lederer, K. Eder, M. Daumer, A. Neiss et al., Relapses and subsequent worsening of disability in relapsing-remitting multiple sclerosis, Neurology, vol.67, issue.5, pp.804-808, 2006.
DOI : 10.1212/01.wnl.0000234064.17156.03

M. Zaffaroni and A. Ghezzi, The prognostic value of age, gender, pregnancy and endocrine factors in multiple sclerosis, Neurological Sciences, vol.21, issue.0, pp.857-860, 2000.
DOI : 10.1007/s100720070026